- en: Clinical Trial Outcome Prediction
  id: totrans-0
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 临床试验结果预测
- en: 原文：[https://towardsdatascience.com/clinical-trial-outcome-prediction-7ce6c27831f9?source=collection_archive---------9-----------------------#2023-10-04](https://towardsdatascience.com/clinical-trial-outcome-prediction-7ce6c27831f9?source=collection_archive---------9-----------------------#2023-10-04)
  id: totrans-1
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 原文：[https://towardsdatascience.com/clinical-trial-outcome-prediction-7ce6c27831f9?source=collection_archive---------9-----------------------#2023-10-04](https://towardsdatascience.com/clinical-trial-outcome-prediction-7ce6c27831f9?source=collection_archive---------9-----------------------#2023-10-04)
- en: 'Part 2: Predicting clinical trial outcomes using XGBoost'
  id: totrans-2
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
  zh: 第2部分：使用XGBoost预测临床试验结果
- en: '[](https://medium.com/@lenlan?source=post_page-----7ce6c27831f9--------------------------------)[![Lennart
    Langouche](../Images/ca35c7112cb845d17e1148b4f282600e.png)](https://medium.com/@lenlan?source=post_page-----7ce6c27831f9--------------------------------)[](https://towardsdatascience.com/?source=post_page-----7ce6c27831f9--------------------------------)[![Towards
    Data Science](../Images/a6ff2676ffcc0c7aad8aaf1d79379785.png)](https://towardsdatascience.com/?source=post_page-----7ce6c27831f9--------------------------------)
    [Lennart Langouche](https://medium.com/@lenlan?source=post_page-----7ce6c27831f9--------------------------------)'
  id: totrans-3
  prefs: []
  type: TYPE_NORMAL
  zh: '[](https://medium.com/@lenlan?source=post_page-----7ce6c27831f9--------------------------------)[![Lennart
    Langouche](../Images/ca35c7112cb845d17e1148b4f282600e.png)](https://medium.com/@lenlan?source=post_page-----7ce6c27831f9--------------------------------)[](https://towardsdatascience.com/?source=post_page-----7ce6c27831f9--------------------------------)[![Towards
    Data Science](../Images/a6ff2676ffcc0c7aad8aaf1d79379785.png)](https://towardsdatascience.com/?source=post_page-----7ce6c27831f9--------------------------------)
    [Lennart Langouche](https://medium.com/@lenlan?source=post_page-----7ce6c27831f9--------------------------------)'
- en: ·
  id: totrans-4
  prefs: []
  type: TYPE_NORMAL
  zh: ·
- en: '[Follow](https://medium.com/m/signin?actionUrl=https%3A%2F%2Fmedium.com%2F_%2Fsubscribe%2Fuser%2F4bee88ffae4&operation=register&redirect=https%3A%2F%2Ftowardsdatascience.com%2Fclinical-trial-outcome-prediction-7ce6c27831f9&user=Lennart+Langouche&userId=4bee88ffae4&source=post_page-4bee88ffae4----7ce6c27831f9---------------------post_header-----------)
    Published in [Towards Data Science](https://towardsdatascience.com/?source=post_page-----7ce6c27831f9--------------------------------)
    ·5 min read·Oct 4, 2023[](https://medium.com/m/signin?actionUrl=https%3A%2F%2Fmedium.com%2F_%2Fvote%2Ftowards-data-science%2F7ce6c27831f9&operation=register&redirect=https%3A%2F%2Ftowardsdatascience.com%2Fclinical-trial-outcome-prediction-7ce6c27831f9&user=Lennart+Langouche&userId=4bee88ffae4&source=-----7ce6c27831f9---------------------clap_footer-----------)'
  id: totrans-5
  prefs: []
  type: TYPE_NORMAL
  zh: '[关注](https://medium.com/m/signin?actionUrl=https%3A%2F%2Fmedium.com%2F_%2Fsubscribe%2Fuser%2F4bee88ffae4&operation=register&redirect=https%3A%2F%2Ftowardsdatascience.com%2Fclinical-trial-outcome-prediction-7ce6c27831f9&user=Lennart+Langouche&userId=4bee88ffae4&source=post_page-4bee88ffae4----7ce6c27831f9---------------------post_header-----------)
    发表在 [Towards Data Science](https://towardsdatascience.com/?source=post_page-----7ce6c27831f9--------------------------------)
    · 5分钟阅读 · 2023年10月4日 [](https://medium.com/m/signin?actionUrl=https%3A%2F%2Fmedium.com%2F_%2Fvote%2Ftowards-data-science%2F7ce6c27831f9&operation=register&redirect=https%3A%2F%2Ftowardsdatascience.com%2Fclinical-trial-outcome-prediction-7ce6c27831f9&user=Lennart+Langouche&userId=4bee88ffae4&source=-----7ce6c27831f9---------------------clap_footer-----------)'
- en: --
  id: totrans-6
  prefs: []
  type: TYPE_NORMAL
  zh: --
- en: '[](https://medium.com/m/signin?actionUrl=https%3A%2F%2Fmedium.com%2F_%2Fbookmark%2Fp%2F7ce6c27831f9&operation=register&redirect=https%3A%2F%2Ftowardsdatascience.com%2Fclinical-trial-outcome-prediction-7ce6c27831f9&source=-----7ce6c27831f9---------------------bookmark_footer-----------)'
  id: totrans-7
  prefs: []
  type: TYPE_NORMAL
  zh: '[](https://medium.com/m/signin?actionUrl=https%3A%2F%2Fmedium.com%2F_%2Fbookmark%2Fp%2F7ce6c27831f9&operation=register&redirect=https%3A%2F%2Ftowardsdatascience.com%2Fclinical-trial-outcome-prediction-7ce6c27831f9&source=-----7ce6c27831f9---------------------bookmark_footer-----------)'
- en: In the [first part of this series](https://medium.com/@lennart.langouche/clinical-trial-outcome-prediction-a4c6d279fd42)
    I focused on embedding multi-modal real-world data derived from [ClinicalTrials.gov](http://clinicaltrials.gov).
    In this article I will implement a basic XGBoost model, train it on the embeddings
    we created in [Part 1](https://medium.com/@lennart.langouche/clinical-trial-outcome-prediction-a4c6d279fd42)
    and compare its performance to that of the HINT model (a hierarchical graph neural
    net) by which this project was inspired.
  id: totrans-8
  prefs: []
  type: TYPE_NORMAL
  zh: 在[本系列的第一部分](https://medium.com/@lennart.langouche/clinical-trial-outcome-prediction-a4c6d279fd42)中，我重点讨论了如何嵌入从[ClinicalTrials.gov](http://clinicaltrials.gov)获取的多模态现实世界数据。在这篇文章中，我将实现一个基本的XGBoost模型，用我们在[第1部分](https://medium.com/@lennart.langouche/clinical-trial-outcome-prediction-a4c6d279fd42)中创建的嵌入进行训练，并将其性能与HINT模型（一个分层图神经网络）的性能进行比较，HINT模型是本项目的灵感来源。
- en: '![](../Images/3562ccfd368279055d7b53f61345d436.png)'
  id: totrans-9
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/3562ccfd368279055d7b53f61345d436.png)'
- en: Workflow schematic (image by author)
  id: totrans-10
  prefs: []
  type: TYPE_NORMAL
  zh: 工作流程示意图（图像由作者提供）
- en: 'These are the steps I will follow in this article:'
  id: totrans-11
  prefs: []
  type: TYPE_NORMAL
  zh: 这是我在本文中将遵循的步骤：
- en: Load training, validation, and test datasets
  id: totrans-12
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: 加载训练、验证和测试数据集
- en: Embed *drug molecule(s), inclusion/exclusion criteria, disease indication(s),
    trial sponsor*, and *number of participants*
  id: totrans-13
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: 嵌入*药物分子、纳入/排除标准、疾病指示、试验赞助商*和*参与者人数*
- en: Define evaluation metrics
  id: totrans-14
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: 定义评估指标
- en: Train XGBoost model and briefly compare with HINT model performance
  id: totrans-15
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: 训练XGBoost模型并简要比较与HINT模型性能
- en: '![](../Images/f95a6a52f07b976351970569dbb08655.png)'
  id: totrans-16
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/f95a6a52f07b976351970569dbb08655.png)'
- en: 'Focus for Part 2 of this series: Predicting clinical trial outcomes based on
    feature embeddings created in [Part 1](https://medium.com/@lennart.langouche/clinical-trial-outcome-prediction-a4c6d279fd42)
    (image by author)'
  id: totrans-17
  prefs: []
  type: TYPE_NORMAL
  zh: 本系列第2部分的重点：基于在[第1部分](https://medium.com/@lennart.langouche/clinical-trial-outcome-prediction-a4c6d279fd42)中创建的特征嵌入预测临床试验结果（图片由作者提供）
- en: 'You can follow all the steps in this Jupyter notebook: [Clinical trial embedding
    tutorial](https://github.com/lenlan/clinical-trial-prediction/blob/main/predict_clinical_trial_outcome_using_XGBoost.ipynb).'
  id: totrans-18
  prefs: []
  type: TYPE_NORMAL
  zh: 你可以按照这个Jupyter notebook中的所有步骤操作：[临床试验嵌入教程](https://github.com/lenlan/clinical-trial-prediction/blob/main/predict_clinical_trial_outcome_using_XGBoost.ipynb)。
- en: Load training, validation, and test datasets
  id: totrans-19
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 加载训练、验证和测试数据集
- en: '[PRE0]'
  id: totrans-20
  prefs: []
  type: TYPE_PRE
  zh: '[PRE0]'
- en: Embed drug molecule, protocol, indication, and trial sponsor
  id: totrans-21
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 嵌入药物分子、方案、指示和试验赞助商
- en: In this section we load the dictionaries we created in [Part 1](https://medium.com/@lennart.langouche/clinical-trial-outcome-prediction-a4c6d279fd42)
    of this series and use them to map the values in the train, validation, and test
    sets into their respective embeddings.
  id: totrans-22
  prefs: []
  type: TYPE_NORMAL
  zh: 在本节中，我们加载了在[第1部分](https://medium.com/@lennart.langouche/clinical-trial-outcome-prediction-a4c6d279fd42)中创建的字典，并使用它们将训练、验证和测试集中的值映射到相应的嵌入中。
- en: '[PRE1]'
  id: totrans-23
  prefs: []
  type: TYPE_PRE
  zh: '[PRE1]'
- en: Define evaluation metrics
  id: totrans-24
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 定义评估指标
- en: 'We will use the same evaluation metrics as the ones proposed in the [HINT article](https://doi.org/10.1016/j.patter.2022.100445):
    ROC AUC, F1, PR-AUC, Precision, Recall, and Accuracy.'
  id: totrans-25
  prefs: []
  type: TYPE_NORMAL
  zh: 我们将使用与[HINT文章](https://doi.org/10.1016/j.patter.2022.100445)中提出的相同的评估指标：ROC
    AUC、F1、PR-AUC、精确度、召回率和准确率。
- en: Train XGBoost model and predict train, validation, and test labels
  id: totrans-26
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 训练XGBoost模型，并预测训练、验证和测试标签
- en: '[PRE2]'
  id: totrans-27
  prefs: []
  type: TYPE_PRE
  zh: '[PRE2]'
- en: Compare performance with HINT model
  id: totrans-28
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 与HINT模型比较性能
- en: 'This simple XGBoost model was trained on feature embeddings for *drug molecule(s),
    inclusion/exclusion criteria, disease indication(s), trial sponsor*, and *number
    of participants* while the HINT authors did not to use the last two features:
    *trial sponsor* and *number of participants.* We used several large language model
    embedding tools such as BioBERT and SBERT, and used Morgan encoding for drug representations
    while the HINT authors used a variety of Neural Nets for all their embeddings.'
  id: totrans-29
  prefs: []
  type: TYPE_NORMAL
  zh: 这个简单的XGBoost模型在*药物分子、纳入/排除标准、疾病指示、试验赞助商*和*参与者人数*的特征嵌入上进行了训练，而HINT作者没有使用最后两个特征：*试验赞助商*和*参与者人数*。我们使用了几个大型语言模型嵌入工具，如BioBERT和SBERT，并采用了Morgan编码进行药物表示，而HINT作者使用了多种神经网络进行所有的嵌入。
- en: We can see from the figure below that our feature embeddings, trained on by
    a simple XGBoost model, perform pretty well compared to the more sophisticated
    HINT model. Our project has better precision and accuracy on this dataset, but
    worse recall.
  id: totrans-30
  prefs: []
  type: TYPE_NORMAL
  zh: 从下面的图中可以看到，我们的特征嵌入在简单的XGBoost模型下的表现相比于更复杂的HINT模型相当好。我们的项目在这个数据集上的精确度和准确性更高，但召回率较低。
- en: '![](../Images/71d338ef8e870b08ccb41d018045cbe7.png)'
  id: totrans-31
  prefs: []
  type: TYPE_IMG
  zh: '![](../Images/71d338ef8e870b08ccb41d018045cbe7.png)'
- en: Comparison of this project’s performance to that of the HINT project (image
    by author)
  id: totrans-32
  prefs: []
  type: TYPE_NORMAL
  zh: 本项目性能与HINT项目的比较（图片由作者提供）
- en: Conclusion
  id: totrans-33
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 结论
- en: Next steps could include doing an analysis to figure out to which extent the
    addition of the features *trial sponsor* and *number of participants* are contributing
    to improved performance (on some metrics) compared to other factors such as model
    choice and embedding techniques. Intuitively, it does seem like these features
    could improve predictive performance, as certain sponsors have historically performed
    better than others, and one might expect a relationship between trial size and
    outcome as well.
  id: totrans-34
  prefs: []
  type: TYPE_NORMAL
  zh: 下一步可能包括分析以确定添加特征*试验赞助商*和*参与者人数*在提高性能（在某些指标上）方面的贡献程度，相较于其他因素，如模型选择和嵌入技术。直观上，这些特征似乎可以提高预测性能，因为某些赞助商的历史表现优于其他人，而且也可以预期试验规模与结果之间存在一定的关系。
- en: 'Now you may wonder: “What is the usefulness of such a predictive model? We
    can’t possibly rely on such a model and forgo running the trial?” And you are
    correct (although some companies are creating digital twins of patients with the
    goal of running trials virtually). A model like the one presented in this series
    could, for example, be used to improve clinical trial power analysis, a related
    statistical practice. A power analysis is used to determine the optimal number
    of participants to enroll in a specific trial, and a strong assumption about the
    treatment effect has to be made to perform such analysis. A predictive model that
    utilizes trial information such as drug molecule structure, disease indication,
    and trial eligibility criteria, like the model we implemented here, can potentially
    help with creating a more accurate power analysis.'
  id: totrans-35
  prefs: []
  type: TYPE_NORMAL
  zh: 现在你可能会想：“这样的预测模型有什么用处？我们不能仅凭这种模型而放弃进行试验吗？”你的想法是正确的（尽管一些公司正在创建患者的数字双胞胎，以期实现虚拟试验）。例如，本系列中展示的模型可以用于改进临床试验的效能分析，这是一种相关的统计实践。效能分析用于确定特定试验中招募参与者的最佳数量，并且需要对治疗效果做出强假设才能进行这种分析。利用试验信息如药物分子结构、疾病指征和试验资格标准的预测模型（例如我们在此实现的模型）可以有助于创建更准确的效能分析。
- en: References
  id: totrans-36
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 参考文献
- en: 'Fu, Tianfan, et al. “Hint: Hierarchical interaction network for clinical-trial-outcome
    predictions.” *Patterns* 3.4 (2022).'
  id: totrans-37
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
  zh: Fu, Tianfan, 等. “提示：用于临床试验结果预测的层级交互网络。” *Patterns* 3.4 (2022).
